The EVIDEM framework and its usefulness for priority setting across a broad range of health interventions
© Youngkong et al; licensee BioMed Central Ltd. 2011
Received: 17 January 2011
Accepted: 19 May 2011
Published: 19 May 2011
This commentary responds to the article by Goetghebeur et al , which applies the EVIDEM (Evidence and Value: Impact on DEcision-Making) framework to evaluate growth hormone therapy for Turner syndrome patients. The EVIDEM framework is developed to assist decision-makers in healthcare decisions, and encompasses a multi-criteria decision analysis (MCDA) matrix consisting of 15 quantifiable, and six qualitative components of decision. With this comprehensive set of criteria, relevant experts can assess the performance of health interventions, and results are input for informed and transparent healthcare decisions.
Goetghebeur et al  propose that the EVIDEM can be used to compare various interventions across disease areas in order to prioritize interventions. They suggest that the EVIDEM can analyze single interventions, and the performance of competing interventions can subsequently be compared in a performance matrix. While we value the qualities of the EVIDEM because of its scope and breadth, we have doubts on the results consistency of the EVIDEM to compare competing interventions, particularly when setting priorities across broad healthcare service areas (e.g. in designing the national health benefit package) for two main reasons.
First, the EVIDEM framework ignores the contextual nature of priority setting process by assuming a set of universal priority setting criteria . In reality, the priority setting process is context specific and different sets of criteria lead priority setting of health interventions in different contexts. As the examples of studies in Nepal , Chile , and Ghana  show, the set of criteria identified for using in priority setting of health interventions were different between countries. Therefore, we suggest that the setting of prioritization criteria needs to be locally determined or verified, implying that the EVIDEM needs to be flexible to allow change/modification of the components to suit the local context.
Secondly, the EVIDEM is vulnerable to interventions ranking inconsistency where performance evaluation of a broad range of competing interventions is mandated. For example, the EVIDEM framework requires different expert panels to assess the performance of every single intervention separately. This may lead to inconsistency of the results as different expert panels may have different considerations across the broad range of interventions to be assessed. As shown in the EVIDEM Turner Syndrome case study , the panel of experts estimated growth hormone intervention to achieve 41% of maximum value. However, in the absence of established explicit weights of criteria, it is not certain that the same panel will be consistent in evaluating different interventions, or that another panel of experts comes up with the same or similar value.
These arguments raise the question whether the approach of EVIDEM is locally meaningful and consistent when priorities are set for a range of interventions. To address its limitations, we propose a stepwise process to identify criteria and their weights, and rank ordered interventions.
We suggest that, to set priorities of a range of interventions within a certain context, a locally-meaningful set of criteria and their relative importance (i.e. weights) should be elicited by consulting relevant stakeholders. As a next step, the identified set of criteria and weights are then used to consistently assess the performance of the broad range of interventions.
Relative importance (Odds ratios) of criteria by perspective
Perspectives (Odds ratios)
Type of intervention
Prevention for non-communicable diseases
Prevention for communicable diseases
Treatment for non-communicable diseases
Treatment for communicable diseases
Target group of intervention
Severity of disease
Number of beneficiaries
Value for money
High cost but low effectiveness
High cost and high effectiveness
Low cost and low effectiveness
Low Cost but high effectiveness
High budget impact
Low budget impact
The explicit weighing of criteria analyzed from DCE may improve the consistency of priority setting across contexts and over time, but does not solve the more fundamental problem that views of stakeholders, and therefore their expressed weights, may diverge. This is acknowledged by the 'Accountability for Reasonableness' (A4R) framework [7, 8] which is based on the believe that any consensus on priority setting weights and subsequent results may be difficult to achieve because of these distinct perspectives of stakeholders. Instead of attempting to resolve the problem of diverse stakeholders' views, the A4R framework proposes to concentrate on a fair priority setting process. On this basis, when conditions of reasonableness, publicity, appeal and enforcement are satisfied, it would lead to decisions that are considered fair and acceptable to stakeholders. We agree with this point of view, and see much scope to integrate MCDA and A4R. The A4R framework has been criticized for not being more operational on the condition of 'reasonableness'  and the explicit definition and weighing of criteria we propose can be a response to that. This will foster the discussion among stakeholders in the priority setting process and render the process, if some consensus is reached on weights, also more consistent.
In summary, the framework of EVIDEM can be a useful tool to assess single intervention or to prioritize between only few interventions; however, in this paper, we place emphasis on the potential of DCE for consistently setting priorities between a range of interventions at once and its meaningfulness across different contexts.
- Goetghebeur M, Wagner M, Khoury H, Rindress D, Grégoire JP, Deal C: Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients. Cost Effectiveness and Resource Allocation 2010, 8: 4. 10.1186/1478-7547-8-4PubMed CentralPubMedView ArticleGoogle Scholar
- Goetghebeur M, Wagner M, Khoury H, Levitt R, Erickson L, Rindress D: Evidence and value: Impact on DEcisionMaking - the EVIDEM framework and potential applications. BMC Health Services Research 2008, 8: 270. 10.1186/1472-6963-8-270PubMed CentralPubMedView ArticleGoogle Scholar
- Baltussen R, Asbroek AHAt, Koolman X, Shrestha N, Bhattarai P, Niessen L: Priority setting using multiple criteria: should a lung health programme be implemented in Nepal? Health Policy and Planning 2007, 22: 178–185. 10.1093/heapol/czm010PubMedView ArticleGoogle Scholar
- Vargas V, Poblete S: Health prioritization: The case of Chile. Health Affairs 2008, 27: 782–792. 10.1377/hlthaff.27.3.782PubMedView ArticleGoogle Scholar
- Jehu-Appiah C, Baltussen R, Acquah C, Aikins M, Amah d'Almeida S, Bosu W, Koolman X, Lauer J, Osei D, Adjei S: Balancing equity and efficiency in health priorities in Ghana: The use of multicriteria decision analysis. Value in Health 2008, 11: 1081–1087. 10.1111/j.1524-4733.2008.00392.xPubMedView ArticleGoogle Scholar
- The International Health Policy Program, Health Intervention and Technology Assessment Program: Research for development of health benefit package under universal health care coverage scheme: Issue 1. Nonthaburi 2011.Google Scholar
- Daniels N: Accountability for reasonableness: Establishing a fair process for priority setting is easier than agreeing on principles. BMJ 2000, 321: 1300–1301. 10.1136/bmj.321.7272.1300PubMed CentralPubMedView ArticleGoogle Scholar
- Daniels N: Just health: Meeting health needs fairly. New York: Cambridge University Press; 2008.Google Scholar
- Friedman A: Beyond accountability for reasonableness. Bioethics 2008, 22: 101–112. 10.1111/j.1467-8519.2007.00605.xPubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.